PRKDC and breast carcinoma: Ku-0060648, an ATP competition inhibitor inhibiting both DNA-PK and PI3K, restrains breast cancer cell proliferation and enhances the sensitivity of breast cancer cells to chemotherapy drugs doxorubicin and Etoposide (65).